On the upcoming virtual Advanced Therapies Congress, Antleron CEO Jan Schrooten will give an e-session lecture entitled 'Turn cells into therapies by end-to-end innovation strategies':
End-to-end innovation strategies can materialize the potential of advanced therapies by creating multi-stakeholder approaches that build on cross-over technologies. As such clinical and industrial translation of advanced therapies synchronizes with regulation, economics and market access. Jan Schrooten’s lecture will focus on how personalized, scalable and sustainable ATMP manufacturing can be enabled by end-to-end innovation strategies that build on quality-by-design based ATMP processes development and digital ATMP factories.
The World Advanced Therapies & Regenerative Medicine Congress is an exhibition and conference that has grown to become one of the best and most established cell and gene events in the world today.
The 2020 edition will be in its 15th year. It attracts representatives of biotech, pharma, payers, regulators, start-ups, investors, researchers and tech companies from around the world.